KGbio
Amalia Indri Senoadji currently serves as the Director at KALGen Innolab, a clinical laboratory specializing in genomics, anatomy pathology, clinical pathology, and microbiology. With a background in business development, Amalia has held various managerial roles in biopharma and nutraceutical companies, including as a General Manager at KGbio. Amalia Indri is also experienced in handling special projects in wound management and dental care. Prior to their current roles, Amalia Indri worked at Novell Pharmaceutical Laboratories. Amalia graduated from the University of Indonesia.
This person is not in any teams
KGbio
KGbio is a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside the US/Canada, Western Europe and China. The business model revolves around in-licensing novel biologics and select biosimilars in oncology and high-specialty therapeutic areas (typically pre-IND or early clinical stage), with the objective to out-license them in target geographies after finishing clinical development as well as regulatory and reimbursement approvals. Platforms of interest currently include Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies and therapeutic vaccines. The company is backed by Asian pharma companies Kalbe (market cap US$5.5 billion) and Genexine (market cap US$1.3 billion) and US private equity giant General Atlantic (AUM US$ 78 billion).